Other DPP4 inhibitors were not included in this meta-analysis
These medications exert (in)direct hepatic actions by reducing steatosis, attenuating inflammation, and potentially reversing fibrosis, while simultaneously addressing systemic metabolic abnormalities including excessive obesity, insulin resistance, and cardiovascular risk
Kidney injury Monitor renal function
Adverse events may be reported to the FDA at 1-800-FDA-1088
Aus dem angenommenen Wirkprofil lassen sich einige theoretisch relevante Konstellationen ableiten, bei denen erhhte Vorsicht angebracht ist: Antikoagulanzien und Thrombozytenaggregationshemmer: Da BPC-157 mit dem Gefsystem und dem NO-System interagiert, sind Effekte auf Durchblutung und Blutgerinnung nicht ausgeschlossen
In a rat migraine model, liraglutide mitigated nitroglycerin-induced sensitization of the trigeminocervical complex, leading to reduced expression of pain mediators such as calcitonin gene-related peptide and c-Fos [23]